Notes - Significant Accounting Policies For Preparation Of Semi-Annual Consolidated Financial Statements
| Concept |
2016-04-01 to 2017-03-31 |
As at 2017-03-31 |
|---|---|---|
| Notes - Significant accounting policies for preparation of semi-annual consolidated financial statements | ||
| Notes - Significant accounting policies for preparation of semi-annual consolidated financial statements | ||
| Disclosure of scope of consolidation | ||
| Number of consolidated subsidiaries and names of major consolidated subsidiaries |
連結子会社数………8社 会社名：杏林製薬㈱ キョーリンメディカルサプライ㈱ Kyorin USA,Inc. Kyorin Europe GmbH ActivX Biosciences,Inc. キョーリンリメディオ㈱ ドクタープログラム㈱ キョーリン製薬グループ工場㈱
|
— |
| Number of consolidated subsidiaries | — |
8
xbrli:pure
|
| Disclosure about application of equity method | ||
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method |
持分法適用の関連会社数……1社 会社名：日本理化学薬品㈱ |
— |
| Number of associates accounted for using equity method | — |
1
xbrli:pure
|
| Disclosure about fiscal years, etc. of consolidated subsidiaries |
３．連結子会社の事業年度等に関する事項 連結子会社のうち、Kyorin USA,Inc.、Kyorin Europe GmbH、ActivX Biosciences,Inc.の決算日は12月31日であります。 連結財務諸表の作成にあたっては、同決算日現在の財務諸表を使用し、連結決算日との間に生じた重要な取引については、連結上必要な調整を行っております。 |
— |